| Literature DB >> 33901655 |
Eduardo M Lacap1, Abraham Varghese1, Faryal Khamis2, Maher Al Bahrani3, Hamed Al Naamani4, Shajidmon Kolamban1, Samata Al Dowaiki5, Huda Salim Al Shuaily1.
Abstract
OBJECTIVE: To develop and validate a clinical score that will identify potential admittance to an intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) case.Entities:
Keywords: COVID-19; Clinical score; Intensive care unit; Oman; Risk factor; SARS-CoV-2
Mesh:
Year: 2021 PMID: 33901655 PMCID: PMC8065243 DOI: 10.1016/j.ijid.2021.04.069
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 12.074
Demographics, laboratory findings, and clinical characteristics of patients with respect to ICU admission.
| Variables | In ICU? | |||
|---|---|---|---|---|
| Total | No | Yes | ||
| No. of valid cases | 313 | 172 | 141 | |
| No. (%), unless specified otherwise | ||||
| Age group | 0.256 | |||
| 40 and below | 96 (31%) | 54 (31%) | 42 (30%) | |
| 41–70 | 181 (58%) | 94 (55%) | 87 (62%) | |
| 71 and above | 36 (11%) | 24 (14%) | 12 (8%) | |
| Male gender | 210 (67%) | 108 (63%) | 102 (72%) | 0.090 |
| Omani nationality | 201 (64%) | 73 (77%) | 68 (48%) | <0.001 |
| Hospitalization, median (IQR), days | 8 (4–14) | 5 (3–8) | 14 (9–22) | <0.001 |
| CURB-65 score | <0.001 | |||
| 0–1 | 225 (72%) | 144 (84%) | 81 (57%) | |
| 2 | 62 (20%) | 22 (13%) | 40 (28%) | |
| 3–5 | 26 (8%) | 6 (3%) | 20 (14%) | |
| No. (%) | ||||
| Diabetes mellitus | 139 (44%) | 70 (41%) | 69 (49%) | 0.170 |
| Hypertension | 145 (46%) | 82 (48%) | 63 (45%) | 0.649 |
| Dyslipidemia | 64 (20%) | 30 (20%) | 34 (21%) | 0.779 |
| Respiratory diseases | 22 (7%) | 12 (7%) | 10 (7%) | 0.968 |
| Heart diseases | 48 (15%) | 32 (19%) | 16 (11%) | 0.084 |
| Liver diseases | 12 (4%) | 9 (5%) | 3 (2%) | 0.237 |
| CKD (eGFR < 70) | 55 (18%) | 39 (23%) | 16 (11%) | 0.011 |
| Alcohol ( | 90 (63%) | 58 (64%) | 32 (63%) | 0.906 |
| No. (%) | ||||
| Fever | 237 (76%) | 126 (73%) | 111 (79%) | 0.291 |
| Urinary tract infection | 180 (58%) | 88 (51%) | 92 (65%) | 0.016 |
| Shortness of breath | 221 (71%) | 100 (58%) | 121 (86%) | <0.001 |
| GI symptoms | 96 (31%) | 64 (37%) | 32 (23%) | 0.007 |
| Chest pain | 43 (14%) | 26 (15%) | 17 (12%) | 0.510 |
| Loss of taste or smell ( | 13 (5%) | 11 (7%) | 2 (2%) | 0.048 |
| Stroke/CNS ( | 19 (6%) | 16 (9%) | 3 (2%) | 0.009 |
| Bilateral infiltrates — chest X-ray abnormality | 234 (75%) | 98 (57%) | 136 (96%) | <0.001 |
| Median (IQR) | ||||
| ALC, × 109/L | 1.00 (0.70–1.40) | 1.10 (0.70–1.50) | 0.90 (0.6–1.2) | <0.001 |
| CRP, mg/dL | 99 (47–168) | 70 (31–132) | 145 (81–203) | <0.001 |
| Ferritin, μg/L | 727 (284–1528) | 553 (128–1205) | 971 (464–1758) | <0.001 |
| Corrected Ca, mm/L ( | 2.04 (1.95–2.13) | 2.06 (1.96–2.15) | 2.02 (1.94–2.10) | 0.095 |
| Vitamin D, ng/mL ( | 62 (44–68) | 64 (44–91) | 59 (46–74) | 0.428 |
| Troponin, ng/mL ( | 15 (8–48) | 14 (7–44) | 16 (9–54) | 0.105 |
| D-dimer, μg/L | 0.77 (0.37–1.79) | 0.51 (0.19–1.04) | 1.06 (0.60–3.27) | <0.001 |
| ALT, U/L | 36 (18–66) | 31 (15–61) | 44 (26–75) | 0.001 |
| Total bilirubin, μmol/L | 9 (6–15) | 8 (5–12) | 10 (7–16) | 0.002 |
| LDH, U/L | 396 (279–545) | 319 (225–418) | 511 (393–660) | <0.001 |
| QTc interval, ms ( | 441 (416–467) | 436 (412–465) | 449 (424–469) | 0.093 |
| <.001 | ||||
| No. (%) | ||||
| Normal | 60 (19%) | 57 (33%) | 3 (2%) | |
| Bilateral infiltrates | 234 (75%) | 98 (57%) | 136 (96%) | <0.001 |
| Unilateral infiltrates | 16 (5%) | 15 (9%) | 1 (1%) | |
| Pleural effusion | 3 (1%) | 2 (1%) | 1 (1%) | |
| No. (%) | ||||
| Asymptomatic ( | 20 (7%) | 18 (12%) | 2 (2%) | |
| Pneumonia ( | 167 (57%) | 120 (73%) | 47 (37%) | <0.001 |
| Severe pneumonia ( | 101 (36%) | 10 (7%) | 91 (68%) | <0.001 |
| ARDS ( | 70 (25%) | 1 (1%) | 69 (53%) | |
| Sepsis ( | 21 (8%) | 7 (5%) | 14 (11%) | 0.046 |
| Myocardial infarction ( | 10 (4%) | 1 (1%) | 9 (7%) | |
Abbreviations: IQR —interquartile range; CURB-65 — confusion, urea, respiratory rate, and blood pressure at age 65 years or older; CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate; CNS — central nervous system; ALC — absolute lymphocyte count; CRP — C-reactive protein; Ca — calcium; ALT — alanine aminotransferase; LDH — lactate dehydrogenase.
Identified as LASSO significant predictor with minimum of λ = 0.02 as tuning parameter for the full model regularization.
Mortality rate: 48 out of 313 (15%).
Chest X-ray result was dichotomized as bilateral infiltrates or not.
Multivariate logistic regression results for building the CoV19-OM ICU score model.
| Variables | Odds ratio (95% CI) | |
|---|---|---|
| Hospitalization period, days | 1.079 (1.058–1.100) | <0.001 |
| Absolute lymphocyte count, × 109/L | 0.526 (0.379–0.729) | 0.049 |
| C-reactive protein, mg/L | 1.009 (1.006–1.011) | <0.001 |
| Lactate dehydrogenase, U/L | 1.0008 (1.0004–1.0012) | 0.041 |
| CURB-65 score | 2.666 (2.212–3.213) | <0.001 |
| CKD (eGFR < 70, yes vs no) | 0.249 (0.155–0.402) | 0.004 |
| Shortness of breath (yes vs no) | 3.949 (2.528–6.168) | 0.002 |
| Bilateral infiltrates — abnormality in X-ray (yes vs no) | 6.335 (3.427–11.713) | 0.003 |
| Constant | 0.005 |
Abbreviations: IQR — interquartile range; CURB-65 — confusion, urea, respiratory rate, and blood pressure at age 65 years or older; CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate.
Figure 1(a) Graphical user interface of the CoV19-OM ICU score web application; (b) Pop-up result; (c) ROC curve for the CoV19-OM ICU score, using the development cohort (0.86).
Characteristics of the validation cohort.
| Variables | In ICU? | ||
|---|---|---|---|
| Total | No | Yes | |
| No. of valid cases | 64 | 19 | 45 |
| No. (%), unless specified otherwise | |||
| Age, years | |||
| 40 and below | 18 (28%) | 7 (37%) | 11 (24%) |
| 41–70 | 40 (63%) | 8 (42%) | 32 (71%) |
| 71 and above | 6 (9%) | 4 (21%) | 2 (4%) |
| Male gender | 50 (78%) | 14 (74%) | 36 (80%) |
| Omani nationality | 27 (42%) | 10 (53%) | 17 (38%) |
| Hospitalization, median (IQR), days | 9.5 (5–18) | 5 (4.5–8.5) | 16 (6–21) |
| Absolute lymphocyte count, median (IQR), × 109/L | 1.05 (0.50–1.50) | 1.20 (0.80–1.50) | 1.00 (0.50–1.40) |
| C-reactive protein, median (IQR), mg/L | 156 (59–244) | 49 (26–134) | 186 (111–260) |
| Lactate dehydrogenase, median (IQR), U/L | 456 (316–592) | 287 (249–414) | 514 (407–637) |
| CURB-65 score, median (IQR) | |||
| 0–1 | 39 (61%) | 17 (89%) | 22 (49%) |
| 2 | 17 (27%) | 22 (11%) | 15 (33%) |
| 3–5 | 8 (13%) | 0 (0%) | 8 (18%) |
| CKD (eGFR < 70, yes vs no) | 6 (9%) | 2 (11%) | 4 (9%) |
| Shortness of breath (yes vs no) | 51 (80%) | 10 (53%) | 41 (91%) |
| Bilateral infiltrates — abnormality in X-ray (yes vs no) | 57 (89%) | 12 (63%) | 45 (100%) |
Abbreviations: IQR — interquartile range; CURB-65 — confusion, urea, respiratory rate, and blood pressure at age 65 years or older; CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate.